860 publications

Name Date Type Actions

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

 		07/09/2023 Public releases

2023 Half-Year Results

Contents
1.H1 2023 Highlights
2.H1 2023 Consolidatedfinancialstatements
3.Strategyand outlook

 		07/09/2023 Half Year Report

Buyback programs - July

Monthly communication regarding buyback programs 
 

 		22/08/2023 Description of buyback programs

Monthly information regarding the total number of voting rights - July 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

 		22/08/2023 Voting rights

Mastaplex and Vetoquinol announce distribution agreement

Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..

 		27/07/2023 Press releases communication

Update July 11, 2023 2023 CALENDAR OF FINANCIAL COMMUNICATION

Update July 11, 2023
Vetoquinol published its calendar of financial communication for 2023.

 		12/07/2023 Agenda

Rapport financier semestriel 2022 (french)

Rapport financier semestriel 2022 (french)

 		26/06/2023 Half Year Report

Growth driven by innovation

Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy.

 		13/06/2023 Press releases communication

Rémunération et politique des dirigeants - mai 2023 (french)

Rémunération et politique des dirigeants
Résultats des votes de l’Assemblée Générale Mixte du 25 mai 2023

 		07/06/2023 Shareholders´s Meeting

Vetoquinol - assemblée générale mixte - 25 mai 2023 : résultat du scrutin

 		26/05/2023 Shareholders´s Meeting